Literature DB >> 24996905

Mutations in HAO1 encoding glycolate oxidase cause isolated glycolic aciduria.

Yaacov Frishberg1, Avraham Zeharia2, Roman Lyakhovetsky3, Ruth Bargal3, Ruth Belostotsky3.   

Abstract

BACKGROUND: The primary hyperoxalurias are a group of recessive kidney diseases, characterised by extensive accumulation of calcium oxalate that progressively coalesces into kidney stones. Oxalate overproduction is facilitated by perturbations in the metabolism of glyoxylate, the product of glycolate oxidation, and the immediate precursor of oxalate. Glycolic aciduria associated with hyperoxaluria is regarded as the hallmark of type 1 primary hyperoxaluria. The genetic basis of isolated glycolic aciduria is reported here. METHODS AND
RESULTS: Two brothers, born to consanguineous healthy parents of Arab descent, were evaluated for psychomotor delay associated with triple-A-like syndrome (anisocoria, alacrima and achalasia). The proband showed markedly increased urinary glycolic acid excretion with normal excretion of oxalate, citrate and glycerate. Abdominal ultrasound showed normal-sized kidneys with normal echotexture. The genetic nature of triple-A-like syndrome in this kindred was found to be unrelated to this metabolic abnormality. Direct DNA sequencing of glycolate oxidase gene (HAO1) revealed a homozygous c.814-1G>C mutation in the invariant -1 position of intron 5 splice acceptor site. Since HAO1 is a liver-specific enzyme, the effect of this novel mutation on splicing was validated by an in vitro hybrid-minigene approach. We confirmed the appearance of an abnormal splice variant in cells transfected with mutant minigene vector.
CONCLUSIONS: Our results pinpoint the expression of defective splice variant of glycolate oxidase as the cause of isolated asymptomatic glycolic aciduria. This observation contributes to the development of novel approaches, namely, substrate reduction, for the treatment of primary hyperoxaluria type I. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.

Entities:  

Keywords:  Clinical Genetics; Metabolic Disorders; Renal Medicine

Mesh:

Substances:

Year:  2014        PMID: 24996905     DOI: 10.1136/jmedgenet-2014-102529

Source DB:  PubMed          Journal:  J Med Genet        ISSN: 0022-2593            Impact factor:   6.318


  27 in total

1.  An Investigational RNAi Therapeutic Targeting Glycolate Oxidase Reduces Oxalate Production in Models of Primary Hyperoxaluria.

Authors:  Abigail Liebow; Xingsheng Li; Timothy Racie; Julia Hettinger; Brian R Bettencourt; Nader Najafian; Patrick Haslett; Kevin Fitzgerald; Ross P Holmes; David Erbe; William Querbes; John Knight
Journal:  J Am Soc Nephrol       Date:  2016-07-18       Impact factor: 10.121

Review 2.  Recent advances in the identification and management of inherited hyperoxalurias.

Authors:  David J Sas; Peter C Harris; Dawn S Milliner
Journal:  Urolithiasis       Date:  2018-12-10       Impact factor: 3.436

3.  Metabolism of (13)C5-hydroxyproline in mouse models of Primary Hyperoxaluria and its inhibition by RNAi therapeutics targeting liver glycolate oxidase and hydroxyproline dehydrogenase.

Authors:  Xingsheng Li; John Knight; Sonia Fargue; Brianna Buchalski; Zhengrong Guan; Edward W Inscho; Abigail Liebow; Kevin Fitzgerald; William Querbes; W Todd Lowther; Ross P Holmes
Journal:  Biochim Biophys Acta       Date:  2015-12-02

Review 4.  Primary hyperoxalurias: diagnosis and treatment.

Authors:  Efrat Ben-Shalom; Yaacov Frishberg
Journal:  Pediatr Nephrol       Date:  2014-12-18       Impact factor: 3.714

Review 5.  Molecular therapy of primary hyperoxaluria.

Authors:  Cristina Martin-Higueras; Armando Torres; Eduardo Salido
Journal:  J Inherit Metab Dis       Date:  2017-04-19       Impact factor: 4.982

6.  siRNA Therapeutics for Primary Hyperoxaluria: A Beginning.

Authors:  Dawn S Milliner
Journal:  Mol Ther       Date:  2016-04       Impact factor: 11.454

Review 7.  RNA interference in the treatment of renal stone disease: Current status and future potentials.

Authors:  Kyle D Wood; Ross P Holmes; John Knight
Journal:  Int J Surg       Date:  2016-11-12       Impact factor: 6.071

8.  Hydroxyproline metabolism in a mouse model of Primary Hyperoxaluria Type 3.

Authors:  Xingsheng Li; John Knight; W Todd Lowther; Ross P Holmes
Journal:  Biochim Biophys Acta       Date:  2015-09-30

9.  Glycolate Oxidase Is a Safe and Efficient Target for Substrate Reduction Therapy in a Mouse Model of Primary Hyperoxaluria Type I.

Authors:  Cristina Martin-Higueras; Sergio Luis-Lima; Eduardo Salido
Journal:  Mol Ther       Date:  2015-12-22       Impact factor: 11.454

10.  Updated genetic testing of Italian patients referred with a clinical diagnosis of primary hyperoxaluria.

Authors:  Alessandra Pelle; Alessandra Cuccurullo; Cecilia Mancini; Regina Sebastiano; Giovanni Stallone; Susanna Negrisolo; Elisa Benetti; Licia Peruzzi; Michele Petrarulo; Mario De Marchi; Martino Marangella; Antonio Amoroso; Daniela Giachino; Giorgia Mandrile
Journal:  J Nephrol       Date:  2016-03-05       Impact factor: 3.902

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.